NeoGenomics, Inc. (NASDAQ:NEO) Q4 2025 Earnings Call Transcript February 17, 2026 NeoGenomics, Inc. misses on earnings ...

What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 10.1% in the afternoon session ...

Q4 2025 earnings call recap: record revenue, RaDaR ST launch, 2026 guidance, margin outlook, and key risks—read now.

NeoGenomics (NASDAQ:NEO) strengthens its position in Nasdaq today with strong institutional backing and growth in ...

In February 2026, NeoGenomics, Inc. announced PanTracer Pro, a new test that combines comprehensive genomic profiling, ...

NeoGenomics will participate in the TD Cowen 46th Annual Health Care Conference in Boston and the Leerink Global Healthcare ...

The Q4 earnings report for NeoGenomics (NASDAQ: NEO) was released on Tuesday, February 17, 2026 at 07:05 AM. Here's what ...

Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on NeoGenomics. NeoGenomics has received a total of ratings ...

For the full year 2025, consolidated revenue increased 10% to $727 million, while the company reported a net loss of $108 million, up from $79 million in 2024. Adjusted EBITDA for 2025 was $43 million ...

NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. I ...

Kendra Webster with NeoGenomics, Inc. The floor is yours. With me today to discuss the results are Anthony P. Zook, Chief ...